Radiology’s Fight Against Prior Authorization Delays
ACR is leading national efforts to make prior authorization more efficient and clinically appropriate while reducing the administrative burden and supporting national legislation.
Read moreMain Content
ARPA-H Announces Program to Include Interventional Radiology
Aug. 7, 2024
The Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services recently announced the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. GLIDE aims to develop physical, pharmacologic, gene and cell-based therapeutic interventions to treat primary and rare lymphatic disease (LD) and chronic conditions complicated by lymphatic dysfunction.
GLIDE’s goals are spread across two technical areas for developing new physical and pharmacological therapies targeting abnormal lymphatic structure and function. Through advances in biomaterials, interventional radiology (IR) and minimally invasive surgical approaches and imaging, GLIDE will accelerate therapeutic options in compression, IR, microsurgery, and other minimally invasive technologies. Additionally, GLIDE will support the development of targeted pharmacologic gene and cell therapies that directly target mechanisms of lymphatic dysfunction to modulate tissue contractility and vessel growth.
For more information on the GLIDE program, ARPA-H will host a Hybrid Proposers' Day Sept. 17.
For more information about American College of Radiology® (ACR®) collaborations with ARPA-H, contact Katie Grady, ACR Government Affairs Director.
GLIDE’s goals are spread across two technical areas for developing new physical and pharmacological therapies targeting abnormal lymphatic structure and function. Through advances in biomaterials, interventional radiology (IR) and minimally invasive surgical approaches and imaging, GLIDE will accelerate therapeutic options in compression, IR, microsurgery, and other minimally invasive technologies. Additionally, GLIDE will support the development of targeted pharmacologic gene and cell therapies that directly target mechanisms of lymphatic dysfunction to modulate tissue contractility and vessel growth.
For more information on the GLIDE program, ARPA-H will host a Hybrid Proposers' Day Sept. 17.
For more information about American College of Radiology® (ACR®) collaborations with ARPA-H, contact Katie Grady, ACR Government Affairs Director.
Related ACR News
ACR Supports Medicaid Coverage of Lung Cancer Screening
ACR-backed bill would mandate Medicaid lung cancer screening, expand cessation coverage, ban prior auth—aiming to save lives and reduce disparities.
Read morePatient-Centered Imaging Care Led by Radiologists
ACR helps its state chapters fight scope of practice expansion, such as helping to oppose bills in state legislatures that would allow non-physicians to practice independently.
Read more